Skip to content
Back to news

A healthy planet for healthy people: our strategy to safeguard environment and fight climate change  

As part of our reinforced targets, we intend to reduce our Scope 1 & 2 emissions by 42% and Scope 3 emissions by 25% by 2030, compared to 2021-2022 levels1. These targets are aligned with the Paris Agreement which aims to limit global temperature increase and thus reduce the risks and impacts of climate change.

In 2022-2023, we reduced our scope 1&2 greenhouse gas emissions by 11% as compared to the previous year. Our efforts are holistic and cover the entire value chain of our medicines. Our main focus is on:

  • Reducing our overall energy consumption and the use of fossil fuels.

In 2022-2023, the Group’s energy consumption levels were reduced by 15% compared with the previous year. We also increased the percentage of renewable energies within our energy mix. For instance, 6 out of our 16 industrial and R&D sites now use only renewable electricity – either produced through solar panels onsite or through procurement of renewable energy.

  • Increasing the proportion of hybrid and electric vehicles, especially by our medical sales representatives.

Part of the Group’s direct emissions come from its car fleet, indispensable to our medical sales representatives. We are currently working on gradually increasing the percentage of hybrid and electric vehicles.

  • Defining a procurement policy that seeks to reduce the carbon footprint of purchased goods and services.

Purchased goods and services account for more than 80% of our emissions. Our tenders systematically include climate-related criteria to assess suppliers. In alignment with our EcoDesign by Servier program, we have also implemented actions such as substituting solvents with lower-emissions alternatives and reviewing our packaging guidelines.

  • Prioritizing marine transport to transport and distribute our medicines.

Air freight is faster but more carbon intensive. In a bid to prioritize a more environmentally responsible means of transport for our medicines, we are gradually increasing the volume of sea freight. In 2022-2023, 57% of our intercontinental flows were transported by the sea, representing a 12% increase in marine transport and a 4% reduction in air transport, as compared to the previous year.

Ecological transition is one of the major challenges of our industry. The impact of climate change on the entire corporate value chain (business models, risks, strategic choices, job profiles, work methods, etc.) is a reality that we must consider.  

Last September, we launched Servier Climate School for Servier employees, in order to create awareness on this topic. The Climate School provides a series of online courses to help understand environmental challenges in business context, as well as to provide guidelines on actions to contribute. With a mix of videos and quizzes, the School is available in multiple languages to ensure accessibility to a maximum number of employees.  

Our approach to the Planet goes beyond to minimizing our impact on biodiversity and nature. We believe that the health and resilience of people and our company depend on the health and resilience of natural ecosystems and their biodiversity.

In 2021, we joined the Act4Nature International alliance which brings together private sector companies, public authorities, scientists, and environment NGOs to create a genuine collective dynamic to protect, enhance and restore biodiversity. A few examples of our actions:

  • Incorporating biodiversity as one of the criteria to source natural raw materials.
  • Reducing the impact of our sites (office building, production sites…) on biodiversity. For example, our Servier R&D Institute in Paris-Saclay is housed in an eco-friendly environment and recently received the BiodiverCity® label with the highest rating (AAAA).  
  • Reducing the water effluents generated by our activities.
  • Raising awareness on biodiversity challenges through Servier Climate School.

To minimize environmental impact, such as reducing carbon emissions, waste, and resource consumption, we integrate ecodesign principles into the lifecycle of medicines, from R&D to the product’s end of life, as well as the purchasing of raw materials, manufacturing, logistics and distribution. A few recent achievements of our program Ecodesign by Servier are as follows:

  • We built recommendations for more eco-friendly packaging for our medicines.
  • We developed “Green Score”, an in-house tool which helps us asses the environmental impact of our chemical synthesis processes used in manufacturing our medicines.
  • We trained selected employees from R&D, Industry and Marketing teams on eco-design principles, and particularly on using “Green Score”. 

At Servier, we are driven by a profound commitment to creating a significant social impact for patients and for a sustainable world. This commitment lies at the heart of our ambition for 2030.

When inspiration meets action: dive into our CSR manifesto video and explore our CSR Report 2022-2023 showcasing our key performance indicators and initiatives as a responsible company.

Read our CSR Report 2022-2023

Read our CSR Report 2022-2023

Watch our manifesto video 

00:00 / 00:00

[1] Scope 1 emissions occur directly from sources that are controlled or owned by the Group. Scope 2 emissions are associated with the purchase of electricity, steam, heat, or cooling. Scope 3 emissions include indirect greenhouse gas emissions from sources outside of our direct control, such as emissions from purchased goods and services, business travel and transportation of products.